



July 27, 2017

## **Cara Therapeutics to Announce Second Quarter 2017 Financial Results on August 3, 2017**

STAMFORD, Conn., July 27, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, August 3, 2017, at 4:30 p.m. ET to report second quarter 2017 financial results and provide a corporate update.

To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 57769313. A live webcast of the call can be accessed under "Events and Presentations" in the News & Investors section of the Company's website at [www.CaraTherapeutics.com](http://www.CaraTherapeutics.com).

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

### **About Cara Therapeutics**

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pruritus and pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

#### INVESTOR CONTACT:

Michael Schaffzin

Stern Investor Relations

212-362-1200

[michael@sternir.com](mailto:michael@sternir.com)

#### MEDIA CONTACT:

Annie Starr

6 Degrees

973-415-8838

[astarr@6degreespr.com](mailto:astarr@6degreespr.com)

 [Primary Logo](#)

Source: Cara Therapeutics Inc.

News Provided by Acquire Media